2
|
Murray E, Hernychová L, Scigelova M, Ho J, Nekulova M, O’Neill JR, Nenutil R, Vesely K, Dundas SR, Dhaliwal C, Henderson H, Hayward RL, Salter DM, Vojtěšek B, Hupp TR. Quantitative Proteomic Profiling of Pleomorphic Human Sarcoma Identifies CLIC1 as a Dominant Pro-Oncogenic Receptor Expressed in Diverse Sarcoma Types. J Proteome Res 2014; 13:2543-59. [DOI: 10.1021/pr4010713] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Euan Murray
- University of Edinburgh, Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, South Crewe Road, Edinburgh EH4 2XR, United Kingdom
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| | - Lenka Hernychová
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| | - Michaela Scigelova
- Thermo Fisher Scientific, Hanna-Kunath-Strasse
11, 28199 Bremen, Germany
| | - Jenny Ho
- Thermo Fisher Scientific, 1
Boundary Park, Hemel Hempstead HP2 7GE, United Kingdom
| | - Marta Nekulova
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| | - John Robert O’Neill
- University of Edinburgh, Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, South Crewe Road, Edinburgh EH4 2XR, United Kingdom
| | - Rudolf Nenutil
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| | - Karel Vesely
- Masaryk University and St. Annés University Hospital, First Department of Pathological Anatomy, Pekařská 53, 656 91 Brno, Czech Republic
| | - Sinclair R. Dundas
- Department
of Pathology, University of Aberdeen, University Medical Buildings, Foresterhill, Aberdeen AB25 2ZD, United Kingdom
| | - Catharine Dhaliwal
- Department
of Pathology, Royal Infirmary of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SA, United Kingdom
| | - Hannah Henderson
- Department
of Pathology, Royal Infirmary of Edinburgh, 49 Little France Crescent, Edinburgh EH16 4SA, United Kingdom
| | - Richard L. Hayward
- University of Edinburgh, Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, South Crewe Road, Edinburgh EH4 2XR, United Kingdom
| | - Donald M. Salter
- University of Edinburgh, Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, South Crewe Road, Edinburgh EH4 2XR, United Kingdom
| | - Bořivoj Vojtěšek
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| | - Ted R. Hupp
- University of Edinburgh, Institute of Genetics and
Molecular Medicine, Edinburgh Cancer Research Centre, South Crewe Road, Edinburgh EH4 2XR, United Kingdom
- RECAMO, Masaryk Memorial Cancer Institute, Žlutý kopec 7, 656 53 Brno, Czech Republic
| |
Collapse
|
3
|
Kondo T, Suehara Y, Kikuta K, Kubota D, Tajima T, Mukaihara K, Ichikawa H, Kawai A. Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. Proteomics Clin Appl 2014; 7:70-8. [PMID: 23281253 DOI: 10.1002/prca.201200085] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2012] [Revised: 10/11/2012] [Accepted: 10/25/2012] [Indexed: 12/16/2022]
Abstract
Sarcomas range from curable tumors to those causing death via metastasis and recurrence. Thus, there is an urgent need for biomarker identification in order to assess the degree of malignancy, predict prognosis, and evaluate possible therapies. Various proteomic approaches and different clinical materials have been used to this end, and candidate biomarkers have been reported for the different types of sarcomas. However, the sample size used in these biomarker studies was generally insufficient, and thus far, no biomarker has been proved useful in clinics. Given that sarcomas are rare, biomarker validation in this setting is more challenging than in other malignancies. In gastrointestinal stromal tumor, adjuvant therapy has proven to be effective. However, only 40% patients experience metastasis after curative surgery alone, and the rest of the patients may not need adjuvant therapy. Using a proteomic approach, we identified pfetin (potassium channel tetramerization domain containing 12, KCTD 12) as a novel prognostic biomarker for sarcoma, and immunohistochemically confirmed its clinical usefulness by a multiinstitutional validation study. Here, we describe our experience and discuss the critical points in the discovery of this biomarker.
Collapse
Affiliation(s)
- Tadashi Kondo
- Division of Pharmacoproteomics, National Cancer Center Research Institute, Tokyo, Japan.
| | | | | | | | | | | | | | | |
Collapse
|